Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.
Saved in:
| Title: | Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence. |
|---|---|
| Authors: | Soeung M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yan X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zanca C; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Qian J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Karki M; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Duan F; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Khan H; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang L; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Peng DH; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Williams M; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., He R; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Chen Z; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Perelli L; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Cancer Biology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Chen J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Tidwell RS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chauhan PK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Le CN; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lam TNA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhattacharya N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA., Ho IL; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gay JP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carrillo CC; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le K; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gao G; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Perry TL; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mseeh F; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jiang Y; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Xu QA; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zacharias NM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sheth RA; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bathala TK; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rao P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daw NC; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tripathi DN; Center for Precision Environmental Health, Baylor college of Medicine, Houston, TX, USA., Walker CL; Center for Precision Environmental Health, Baylor college of Medicine, Houston, TX, USA., Mohammad MM; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dang M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dai E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Peng F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jadhav A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lang W; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Arrechedera CA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Clemente LC; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Viale A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Soth MJ; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jones P; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Marszalek JR; Institute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Heffernan T; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Draetta GF; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jgao1@mdanderson.org.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. jgao1@mdanderson.org., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lwang22@mdanderson.org.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA. lwang22@mdanderson.org.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lwang22@mdanderson.org.; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lwang22@mdanderson.org., Genovese G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ggenovese@mdanderson.org.; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ggenovese@mdanderson.org.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ggenovese@mdanderson.org.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. ggenovese@mdanderson.org., Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pmsaouel@mdanderson.org.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. pmsaouel@mdanderson.org.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA. pmsaouel@mdanderson.org.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pmsaouel@mdanderson.org. |
| Source: | Nature communications [Nat Commun] 2025 Nov 25; Vol. 16 (1), pp. 10474. Date of Electronic Publication: 2025 Nov 25. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-65462-z |
